← Eichor
Condition: Egfr Mutation Positive Advanced Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Egfr Mutation Positive Advanced Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Lo
Phase 2 · 7 location(s) · OBI Pharma, Inc · NCT05442060A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC
Phase 2 · 4 location(s) · Guangdong Association of Clinical Trials · NCT07375316APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2 · 26 location(s) · Sun Yat-sen University · NCT05334277Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
Phase 1/Phase 2 · 12 location(s) · Wayshine Biopharm, Inc. · NCT06631989ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2 · 1 location(s) · Fudan University · NCT06775743A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Trea
Phase 1/Phase 2 · 5 location(s) · Henan Genuine Biotech Co., Ltd. · NCT07231068Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced
Phase 3 · 166 location(s) · AstraZeneca · NCT06350097A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR
Phase 2 · 1 location(s) · Peng Zhang · NCT06755684A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07058519The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Phase 1/Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06109558A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Phase 1 · 6 location(s) · Nuvectis Pharma, Inc. · NCT07315113A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 5 location(s) · Avistone Biotechnology Co., Ltd. · NCT07538804Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Adv
Phase N/A · 1 location(s) · Second Xiangya Hospital of Central South University · NCT05598528
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.